Literature DB >> 32023597

[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].

Masao Hagihara1, Shiro Ide1, Shin Ohara1, Tomoyuki Uchida1, Morihiro Inoue1, Jian Hua1.   

Abstract

We retrospectively evaluated the efficacy of pomalidomide/cyclophosphamide/dexamethasone (PCd) treatment in seven patients with extramedullary disease (EMD). Three of the seven patients achieved VGPR (very good partial response) with PCd therapy. We handled a patient complicated with secondary plasma cell leukemia, which was completely cured with PCd regimen and succeeded to autologous stem cell transplantation. In addition, there were no severe infections during the treatment period. This is the first report demonstrating the efficiency and tolerability of PCd treatment for EMD.

Entities:  

Keywords:  Cyclophosphamide; Extramedullary myeloma; Pomalidomide

Mesh:

Substances:

Year:  2020        PMID: 32023597     DOI: 10.11406/rinketsu.61.20

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.

Authors:  Junhui Xu; Liang Gao; Miao Yan; Bingjie Wang; Zhengyang Song; Huihui Liu; Kunyan Sun; Lin Nong; Mangju Wang; Xinan Cen
Journal:  Onco Targets Ther       Date:  2021-08-24       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.